To include your compound in the COVID-19 Resource Center, submit it here.

Alcon fails AMD Phase III

ACL said an initial analysis of one-year Phase III data showed that 15 mg of its Retaane anecortave acetate depot missed the primary endpoint of

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE